Understanding Weight Regain After Tirzepatide Withdrawal
By
Fengning Chuan
Youyuan Gao
Bo Zhou
June 1, 2026
Objective: To analyze the cardiometabolic consequences of weight regain after discontinuation of tirzepatide therapy based on the SURMOUNT-4 trial.
Key Findings: Rephrase to avoid suggesting causation or conclusions. Interpretation: Remove or rephrase to reflect only the findings without unsupported implications.
Limitations: The study did not measure hormonal mediators that could predict individual susceptibility to weight regain. Uncertainty exists regarding adherence to diet and exercise recommendations post-therapy. Lack of body composition data prevents assessment of the true metabolic cost of weight regain. Conclusion: Revise to reflect only findings without recommendations for future research.
